Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 42c, Beats on Revenue; Offers FY25 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Ionis reports third quarter 2025 financial results and highlights progress on key programs
October 29, 2025 7:00 AM EDT- TRYNGOLZA® generated $32 million in net product sales in the third quarter 2025 -
- DAWNZERA (donidalorsen) launch off to encouraging start -
- Olezarsen significantly reduced triglycerides and acute pancreatitis events in severe hypertriglyceridemia (sHTG) in landmark Phase 3 studies; sNDA submission on track by year-end
- Positive pivotal zilganersen results in Alexander disease position Ionis for first independent neurology launch in 2026 -
- Increasing 2025 financial guidance driven by continued strength across the business
CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis... More
